Imara M&A

BLI (photons/sx106) ELVN-002 Demonstrated Robust CNS Anti-Tumor Activity in NCI-N87 HER2 amp Intracranial Model at Well-Tolerated Doses 200- 150- 100- 50- ● ● 0 NCI-N87 HER2wt Intracranial (CNS) Model H HOCHIL 10 Days post treatment 20 HH100 Vehicle Tucatinib 50 mg/kg BID Tucatinib 75 mg/kg BID ELVN-002 10 mg/kg QD ELVN-002 20 mg/kg QD ELVN-002 50 mg/kg QD Concentration (ng/mL) BID = Twice a day. QD = Once a day Tucatinib 300 mg BID (tablet) human AUCtau ~5,234 ng*hr/mL (NDA); mouse 50 mg/kg BID AUC ~47,300 ng*hr/mL (combined), mouse 75 mg/kg BID AUC ~123,000 ng*hr/mL (combined) (internal data) ELVN-002 10 mg/kg nude mouse AUC ~1,260 ng*hr/mL 10000- 1000- 100- 10- 0 Tucatinib vs. ELVN-002 Nude Mouse PK 10 hours 20 ELVN-002 yielded sustained tumor regressions in the NCI-N87 intracranial model, and all doses tested were well-tolerated Tucatinib treatment of 50 & 75 mg/kg BID results in ~4.5x & ~12x its human exposure at 300 mg BID ELVN-002 exhibited superior CNS anti-tumor activity at ~40-100x lower exposures compared to tucatinib in this model Tucatinib 75 mg/kg BID Tucatinib 50 mg/kg BID ELVN-002 10 mg/kg QD Tucatinib pHER2 WT IC90 (100% human serum) Tucatinib pHER2 WT IC50 (100% human serum) 41

View entire presentation